Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza
| Autor: | Margaret Tisdale, Stephen J. Sharp, Chantelle Ward, Raija Vainionpää, Heikki Lehti, Caron Kerr, Maria Dempsey, Tuomo Puhakka, Christopher J. Ring, Vesa Jormanainen, Markku Pulkkinen |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
viruses Administration Oral Guanidines Polymerase Chain Reaction Severity of Illness Index 0302 clinical medicine Reference Values Clinical endpoint Medicine Zanamivir 030212 general & internal medicine Finland 0303 health sciences Area under the curve virus diseases General Medicine Viral Load Orthomyxoviridae 3. Good health Infectious Diseases Military Personnel Treatment Outcome RNA Viral Female Viral disease Viral load medicine.drug Microbiology (medical) Adult medicine.medical_specialty Molecular Sequence Data Placebo Drug Administration Schedule 03 medical and health sciences Double-Blind Method Internal medicine Influenza Human Confidence Intervals Humans Probability Pyrans General Immunology and Microbiology Base Sequence Dose-Response Relationship Drug 030306 microbiology business.industry Confidence interval Immunology Sialic Acids business Follow-Up Studies |
| Zdroj: | Scandinavian journal of infectious diseases. 35(1) |
| ISSN: | 0036-5548 |
| Popis: | A randomized, double-blind, placebo-controlled, parallel-group trial performed at 5 residential units of the Finnish Defence Forces was conducted to assess the antiviral activity, efficacy and safety of inhaled zanamivir for the treatment of naturally acquired influenza. Conscripts were recruited within 2 d of onset of typical influenza symptoms and received inhaled zanamivir 10 mg via a Diskhaler twice daily for 5 d or matching placebo. Time to alleviation of clinically significant symptoms of influenza was the primary endpoint. Viral load measurements were made using quantitative real-time polymerase chain reaction assays. 435/588 patients (74%) had laboratory-confirmed influenza infection. The mean area under the curve for viral load during the first 48 h of treatment was 8.48 [95% confidence interval (95% CI) 2.85 to 14.11] log10 vRNA copies/ml x h lower in the zanamivir group compared with placebo (p = 0.003). Zanamivir reduced the time to alleviation of symptoms versus placebo in the influenza-positive group (medians 2.0 vs 2.33 d; 95% CI-0.17 to 1.0 d, p = 0.08). Zanamivir rapidly reduced viral load following the start of therapy compared with placebo and was well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|